Follow The Filings

BBNX Beta Bionics Inc.

Health Care, filed as BETA BIONICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 1 Owner
  • Max 0.0%
  • $9.3M
  • 1 reduce 1 exit

In 2026 Q2 Farallon Capital Management trimmed Beta Bionics, and First Eagle Investment Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.0% (Farallon Capital Management). Not free-float ownership.

  1. Farallon Capital Management Reduce 0.04%

Who owns BBNX

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management 0.04%, was 0.20% Reduce −83.5% 595,000 $9.3M History
First Eagle Investment Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 242,000 $2.4M History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BBNX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BBNX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $3.1M sold by 7 insiders under 10b5-1 plans
  1. Mike Mensinger Chief Product Officer
    Planned sale
    $58K 2,650 shares at $22.00 1.5% of stake
    Traded Oct 27 Filed Oct 29
    ↗
  2. Mark Hopman Chief Commercial Officer
    Planned sale
    $16K 821 shares at $20.00 1.5% of stake
    Traded Oct 26 Filed Oct 28
    ↗
  3. Mark Hopman Chief Commercial Officer
    Planned sale
    $13K 775 shares at $17.35 1.4% of stake
    Traded Oct 14 Filed Oct 16
    ↗
  4. Mark Hopman Chief Commercial Officer
    Planned sale
    $7,015 370 shares at $18.96 0.7% of stake
    Traded Oct 1 Filed Oct 5
    ↗
  5. Christy Jones Director
    Planned sale
    $148K 6,430 shares at $23.00 25% of stake
    Traded Sep 22 Filed Sep 23
    ↗
  6. Mark Hopman Chief Commercial Officer
    Planned sale
    $665K 35,994 shares at $18.46 29% of stake
    Traded Sep 9 Filed Sep 18
    ↗
  7. Mike Mensinger Chief Product Officer
    Planned sale
    $58K 2,650 shares at $22.00 1.5% of stake
    Traded Sep 16 Filed Sep 17
    ↗
  8. Mark Hopman Chief Commercial Officer
    Planned sale
    $620K 30,779 shares at $20.13 35% of stake
    Traded Sep 16 Filed Sep 17
    ↗
  9. Mark Hopman Chief Commercial Officer
    Planned sale
    $12K 775 shares at $15.52 0.9% of stake
    Traded Sep 14 Filed Sep 15
    ↗
  10. Sean Saint CEO
    Planned sale
    $113K 5,641 shares at $20.08 1.4% of stake
    Traded Sep 3 Filed Sep 4
    ↗
  11. Stephen Feider CFO
    Planned sale
    $170K 10,000 shares at $17.04 5.7% of stake
    Traded Jun 26–29 Filed Jul 2
    ↗
  12. Mark Hopman Chief Commercial Officer
    Planned sale
    $19K 1,258 shares at $15.01 1% of stake
    Traded Jun 24 Filed Jun 25
    ↗
  13. Christy Jones Director
    Planned sale
    $21K 1,406 shares at $15.00 5.1% of stake
    Traded Jun 24 Filed Jun 25
    ↗
  14. Mark Hopman Chief Commercial Officer
    Planned sale
    $3,385 275 shares at $12.31 0.2% of stake
    Traded Jun 4 Filed Jun 5
    ↗
  15. Christy Jones Director
    Planned sale
    $39K 2,811 shares at $14.00 9.3% of stake
    Traded Jun 4 Filed Jun 5
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 sales to cover taxes, 17 stock grants, and 3 option exercises.

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2024 FY2025
Revenue $65.12M $100.25M
Gross profit $35.89M $55.54M
Gross margin * 55.1% 55.4%
Net income -$54.76M -$73.2M
Net margin * -84.1% -73.0%

Balance sheet

Metric FY2024 FY2025
Total current assets $132.92M $267.9M
Total non-current assets * $16.72M $60.84M
Total assets $149.64M $328.74M
Total current liabilities $21.15M $30.92M
Total non-current liabilities * $52.48M $10.21M
Total equity -$245.36M $287.61M

Cash flow

Metric FY2024 FY2025
Cash from operations -$48.27M -$50.92M
Cash from investing -$3.48M -$162.8M
Cash from financing $55.62M $214.87M
Net change in cash $3.87M $1.14M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.